Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Agonism of the glucagon-like peptide-1 receptor (GLP-1R) results in glycemic lowering and body weight loss and is a therapeutic strategy to treat type 2 diabetes (T2D) and obesity. We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R agonist and found it had comparable efficacy to i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2021-06, Vol.27 (6), p.1079-1087
Hauptverfasser:	Saxena, Aditi R., Gorman, Donal N., Esquejo, Ryan M., Bergman, Arthur, Chidsey, Kristin, Buckeridge, Clare, Griffith, David A., Kim, Albert M.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/153 692/308/575 Adverse events Agonists Biomedical and Life Sciences Biomedicine Blood pressure Body weight Body weight loss Cancer Research Diabetes Diabetes mellitus (non-insulin dependent) Drug therapy Dyspepsia EKG Electrocardiography GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Heart rate Hypoglycemic agents Infectious Diseases Laboratories Laboratory tests Metabolic Diseases Metformin Molecular Medicine Nausea Neurosciences Pharmacokinetics Placebos Receptors Safety Testing Type 2 diabetes Vomiting Weight loss
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!